Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$128.91 USD
+0.68 (0.53%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $128.84 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NBIX 128.91 +0.68(0.53%)
Will NBIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for NBIX
Neurocrine (NBIX) Receives Upgraded Price Target After Strong Earnings
Guggenheim Raises Price Target for NBIX, Maintains "Buy" Rating | NBIX Stock News
Neurocrine price target raised by $10 at Guggenheim, here's why
NBIX: RBC Capital Maintains Rating but Lowers Price Target | NBIX Stock News
NBIX: Stifel Raises Price Target to $174, Reiterates Buy Rating | NBIX Stock News